Medpace (NASDAQ:MEDP) CEO August Troendle Sells 3,728 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 3,728 shares of the firm’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $600.85, for a total value of $2,239,968.80. Following the transaction, the chief executive officer owned 642,456 shares in the company, valued at approximately $386,019,687.60. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $585.49 on Thursday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The business has a 50-day moving average of $501.76 and a two-hundred day moving average of $493.30. The stock has a market capitalization of $16.34 billion, a P/E ratio of 34.32, a P/E/G ratio of 2.55 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MEDP has been the topic of several analyst reports. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Mizuho raised their target price on shares of Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Finally, Robert W. Baird lifted their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $584.18.

Institutional Investors Weigh In On Medpace

Several hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. grew its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the 4th quarter valued at $30,000. Elyxium Wealth LLC bought a new stake in Medpace in the 4th quarter valued at $30,000. Allied Private Wealth LLC bought a new stake in Medpace in the 2nd quarter valued at $31,000. Finally, Basecamp Wealth Advisors LLC boosted its holdings in Medpace by 187.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after purchasing an additional 45 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.